Ischemic acute renal failure remains a common cause of renal failure in the hospital setting. In spite of substantial investigation, the prognosis for this type of renal failure has not significantly improved. We and others have shown that complement activation is an important event in the development of ischemic acute renal failure in mice. The proposed studies aim to analyze the mechanisms of complement activation and complement dependent injury in models of ischemic acute renal failure. Experiments will also be conducted to determine whether a newly created inhibitor of the alternative complement pathway is of therapeutic benefit in these models of injury. Given the complexity of ischemic injury in the kidney, several in vivo and in vitro models will be used. These include the in vivo induction of ischemic acute renal failure in mice, and subjection of freshly isolated renal tubules to hypoxia in the presence or absence of complement factors. Many of the in vivo experiments will utilize mice that are deficient in specific complement activation pathway components or in the inhibitors of complement (i.e. knockout mice). The techniques used to measure the endpoints of these experiments include assays for serum urea nitrogen, light microscopy, immunofluorescence of cells in culture and of tissue sections, ELISA, Westem blot analysis, gene array analysis, and quantitative RT-PC1L In addition, some unique assays developed by our collaborators will be utilized, such as a method of measuring caspase activation. These experiments are designed to analyze in depth the complement dependent mechanisms of injury which occur during renal ischemia/reperfusion. The techniques used will utilize the expertise of experts in the fields of complement biology as well as acute renal failure. The purpose of these studies is to ameliorate ischemic ARF by blocking these pathogenic events, and to develop strategies for decreasing the morbidity and mortality associated with ischemic ARF in humans.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DK064790-04
Application #
7095096
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Rankin, Tracy L
Project Start
2003-08-01
Project End
2008-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
4
Fiscal Year
2006
Total Cost
$132,490
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Renner, Brandon; Ferreira, Viviana P; Cortes, Claudio et al. (2011) Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int 80:165-73
Tchepeleva, Svetlana N; Thurman, Joshua M; Ruff, Katherine et al. (2010) An allelic variant of Crry in the murine Sle1c lupus susceptibility interval is not impaired in its ability to regulate complement activation. J Immunol 185:2331-9
Sesarman, A; Mihai, S; Chiriac, M T et al. (2008) Binding of avian IgY to type VII collagen does not activate complement and leucocytes and fails to induce subepidermal blistering in mice. Br J Dermatol 158:463-71
Clark, Amelia; Weymann, Alexander; Hartman, Eric et al. (2008) Evidence for non-traditional activation of complement factor C3 during murine liver regeneration. Mol Immunol 45:3125-32
Babu, Ashok N; Murakawa, Tomohiro; Thurman, Joshua M et al. (2007) Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J Clin Invest 117:3774-85
Thurman, Joshua M (2007) Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol 123:7-13
Thurman, Joshua M; Lenderink, Amanda M; Royer, Pamela A et al. (2007) C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol 178:1819-28
Lenderink, Amanda M; Liegel, Katharine; Ljubanovic, Danica et al. (2007) The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am J Physiol Renal Physiol 293:F555-64
Mihai, Sidonia; Chiriac, Mircea T; Takahashi, Kazue et al. (2007) The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J Immunol 178:6514-21
Taube, Christian; Thurman, Joshua M; Takeda, Katsuyuki et al. (2006) Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc Natl Acad Sci U S A 103:8084-9

Showing the most recent 10 out of 18 publications